|
Age(years)
|
|
< 65
|
1.0
|
1.0
|
|
> 65
|
5.70 (3.28–9.92)
|
2.31 (1.13–4.73)
|
|
Medical insurance coverage
|
|
High (> 70%)
|
1.0
|
1.0
|
|
Medium (50–70%)
|
2.36 (1.28–4.36)
|
3.21 (1.53–6.73)
|
|
Low (< 50%)
|
2.86 (1.44–5.66)
|
3.58 (1.57–8.15)
|
|
Family history
|
|
Negative
|
1.0
| |
|
Positive
|
1.24 (0.47–3.24)
| |
|
Marital status
|
|
Married
|
1.0
| |
|
Unmarried
|
2.20 (0.93–5.19)
| |
|
Employment status
|
|
Employed
|
1.0
| |
|
Unemployed
|
1.15 (0.58–2.28)
| |
|
Retired
|
0.77 (0.42–1.41)
| |
|
Tumor size (cm)
|
|
0–1.9
|
1.0
| |
|
2–4.9
|
1.28 (0.79–2.09)
| |
|
> 5
|
2.44 (0.89–6.68)
| |
|
Positive axillary nodal status
|
|
0
|
1.0
| |
|
1–3
|
1.15 (0.68–1.94)
| |
|
4–9
|
1.74 (0.82–3.69)
| |
|
> 10
|
1.47 (0.55–3.96)
| |
|
TNM stage
|
|
Stage 0-I
|
1.0
| |
|
Stage II
|
1.17 (0.70–1.95)
| |
|
Stage III
|
1.44 (0.73–2.83)
| |
|
Histological subtype
|
|
In Situ
|
1.0
| |
|
Ductal/Lobular/Mixed/Metaplastic
|
0.49 (0.11–2.08)
| |
|
Tubular/Mucinous/Papillary
|
0.13 (0.01–1.54)
| |
|
ER
|
|
Negative
|
1.0
| |
|
Positive
|
1.32 (0.79–2.20)
| |
|
PR
|
|
Negative
|
1.0
| |
|
Positive
|
1.24 (0.76–2.01)
| |
|
HER2
|
|
Negative
|
1.0
| |
|
Positive
|
0.84 (0.47–1.52)
| |
|
Surgery of breast
|
|
Lumpectomy
|
1.0
| |
|
Mastectomy
|
1.37 (0.86–2.18)
| |
|
Axillary surgery
|
|
Sentinel lymph node biopsy
|
1.0
|
1.0
|
|
Axillary lymph node dissection
|
1.57 (0.97–2.53)
|
2.51 (1.39–4.52)
|
|
Chemotherapy
|
|
Yes
|
1.0
|
1.0
|
|
No
|
5.27 (3.19–8.70)
|
3.48 (1.84–6.57)
|
|
Radiotherapy
|
|
Yes
|
1.0
|
1.0
|
|
No
|
5.32 (3.25–8.71)
|
3.90 (2.14–7.10)
|
|
Targeted therapy
|
|
Yes
|
1.0
| |
|
No
|
3.24 (1.13–9.28)
| |
|
Endocrine therapy
|
|
Yes
|
1.0
| |
|
No
|
1.65 (1.03–2.64)
| |
